Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
2005-04-29
2010-02-16
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C530S324000
Reissue Patent
active
RE041133
ABSTRACT:
The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.
REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5512549 (1996-04-01), Chen et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5734026 (1998-03-01), Florin-Robertsson et al.
patent: 5780599 (1998-07-01), Junker et al.
patent: 5977071 (1999-11-01), Galloway et al.
patent: 6284727 (2001-09-01), Kim et al.
patent: 6380357 (2002-04-01), Hermeling et al.
patent: 0619322 (1994-10-01), None
patent: 0658568 (1995-06-01), None
patent: 0869135 (1998-10-01), None
patent: WO 93/25579 (1993-12-01), None
patent: WO 95/05848 (1995-03-01), None
patent: WO 96/20005 (1996-07-01), None
patent: WO 97/15296 (1997-05-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/19698 (1998-05-01), None
patent: WO 98/20895 (1998-05-01), None
Komatsu, R., et al., Diabetes, 38:902-905, 1989.
Orskov, C., et al., J. Biol. Chem., 264(22):12826-12829, 1989.
Majsov, S., Int. J. Peptide Protein Res., 40:33-343, 1989.
Holz, G., et al., Nature, 361:362-365, 1993.
Orkov, C., Diabetologia, 35:701-711, 1992.
Mentlein, R., et al., Eur. J. Biochem., 214:829-835, 1993.
Nauck, M. A., et al., J. Clin. Invest., 91:301-307, 1993.
Nauck, M. A., et al., Diabetologia, 36:741-744, 1993.
Gutniak, M., et al., N.E.J. Med., 326(20):1316-1322, 1992.
Thorens, B., et al., Diabetes, 42:1219-1225, 1993.
Suzuki, S., et al., Endocrinology, 125:3109-3114, 1990.
Ananthanancayanan, V. V., et al., Mol. Biol. Cell (Supp.), 3, 250A, #1452, 1992.
Epand, R.M., Mol. Pharmacol., 22:105-108, 1982.
Kim, Y., et al., Pharm. Res., 12:1664-1670, The Application of Crystal Soaking Technique to Study the Effect of Zinc and Cresol on Insulinotropin Crystals Grown from a Saline Solution, 1995.
Naslund, E., et al., Drug News Perspect, 11:92-97, 1998.
Naslund, E. et al., Am. J. Clin. Nutr., 68:525-530, 1998.
Flint, A., et al., J. Clin. Invest., 101:515-520, 1998.
Lone Pridal, et al., International Journal of Pharmaceutics, 136:53-59, Absorption of glucagon-like peptide-1 can be protracted by zinc or protamine, 1996.
Hermeling Ronald Norbert
Hoffmann James Arthur
Narasimhan Chakravarthy N. N.
Castetter Andrea M.
Cox Gregory A.
Eli Lilly and Company
Russel Jeffrey E
Stewart Mark J.
LandOfFree
Glucagon-like peptide-1 crystals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucagon-like peptide-1 crystals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon-like peptide-1 crystals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4206668